Mirae Asset Global Etfs Holdings Ltd. Summit Therapeutics Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $56.2 Billion
- Q3 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 17,996 shares of SMMT stock, worth $328,247. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,996
Previous 10,311
74.53%
Holding current value
$328,247
Previous $219,000
70.32%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding SMMT
# of Institutions
261Shares Held
93.5MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...